Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.89M | 13.44M | -23.86M | -30.31M | -31.97M |
| Total Depreciation and Amortization | 2.65M | 2.56M | 2.70M | 2.26M | 2.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.61M | 3.27M | 2.59M | 3.21M | 4.00M |
| Change in Net Operating Assets | -98.64M | 109.65M | -2.43M | -2.93M | -12.90M |
| Cash from Operations | -45.49M | 128.92M | -20.99M | -27.77M | -38.17M |
| Capital Expenditure | -1.59M | -183.00K | -399.00K | -2.02M | -1.38M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -98.64M | -30.71M | 38.15M | -59.14M | 11.24M |
| Cash from Investing | -100.23M | -30.90M | 37.75M | -61.16M | 9.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14.00K | 3.61M | 15.00K | 48.66M | 246.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -3.00M | 0.00 | 49.36M | -- |
| Cash from Financing | 14.00K | 608.00K | 15.00K | 98.02M | 246.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -145.71M | 98.63M | 16.77M | 9.10M | -28.07M |